GNS Co-Founder Iya Khalil Interviewed in The Pink Sheet

At the 2017 BIO International Convention, GNS Co-Founder and Chief Commercial Officer Iya Khalil sat down with Laura Helbling, the Director of Research at Prevision Policy and a Senior Writer at Pink Sheet to discuss machine learning in drug development. The conversation focused on how GNS’ causal machine learning and simulation platform applied to massive […]

GNS Healthcare Licenses REFS™ Causal Machine Learning and Simulation Platform to Alexion to Accelerate Discovery of New Treatments for Rare Diseases

CAMBRIDGE, Mass. – August 10, 2017– GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to large and diverse data sets to better match drugs and other health interventions to individual patients, today announced that it has entered into a license arrangement with Alexion for the rights to operate its REFS™ […]

Global Genomics Group (G3) and GNS Healthcare Report Preliminary Results of Largest-Ever Study Linking Biomarkers with Coronary Artery Disease

Study Applies GNS’s Causal Machine Learning to G3’s G3LOBAL DatabaseTM Study Demonstrates Proof of Concept of Approach with Identification of Known Coronary Disease-Associated Pathway ATLANTA, Ga. and CAMBRIDGE, Mass. – Jan. 8, 2016 – Global Genomics Group (G3), a life sciences company that leverages large-scale genomic and molecular disease profiles to develop life-changing diagnostics and therapeutics, […]

Cognitive technologies: The real opportunities for business

Aetna and GNS Healthcare collaboration exemplifies how cognitive technologies can create knowledge from massive amounts of data Computers cannot think. But increasingly, they can do things only humans were able to do. It is now possible to automate tasks that require human perceptual skills, such as recognizing handwriting or identifying faces, and those that require […]